1 McAlpine J,Leon-Castillo A,Bosse T.The rise of a novel classification system for endometrial carcinoma,integration of molecular subclasses.J Pathol,2018,244:538-549. 2 Brooks RA,Fleming GF,Lastra RR,et al.Current recommendations and recent progress in endometrial cancer.CA Cancer J Clin,2019,69:258-279. 3 Chaussabel D,Baldwin N.Democratizing systems immunology with modular transcriptional repertoire analyses.Nat Rev Immunol,2014,14:271-280. 4 Li S,Rouphael N,Duraisingham S,et al.Molecular signatures of antibody responses derived from a systems biology study of five human vaccines.Nat Immunol,2014,15:195-204. 5 Yoshihara K,Shahmoradgoli M,Martínez E,et al.Inferring tumour purity and stromal and immune cell admixture from expression data.Nat Commun,2013,4:2612. 6 Shah N,Wang P,Wongvipat J,et al.Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.Elife,2017,6. 7 Bhattacharya S,Andorf S,Gomes L,et al.ImmPort:disseminating data to the public for the future of immunology.Immunol Res,2014,58:234-239. 8 Liu GM,Zeng HD,Zhang CY,et al.Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma.Cancer Cell Int ,2019,19:138. 9 Liu J,Nie S,Wu Z,et al.Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironment.Genomics,2020,112:3117-3134. 10 Dossus L,Lukanova A,Rinaldi S,et al.Hormonal,metabolic,and inflammatory profiles and endometrial cancer risk within the EPIC cohort-a factor analysis.Am J Epidemiol,2013,177:787-799. 11 Hanahan D,Coussens LM.Accessories to the crime:functions of cells recruited to the tumor microenvironment.Cancer Cell,2012,21:309-322. 12 Büttner R,Longshore JW,López-Ríos F,et al.Implementing TMB measurement in clinical practice:considerations on assay requirements.ESMO Open,2019,4:e000442. 13 Baretti M,Le DT.DNA mismatch repair in cancer.Pharmacol Ther,2018,189:45-62. 14 Samstein RM,Lee CH,Shoushtari AN,et al.Tumor mutational load predicts survival after immunotherapy across multiple cancer types.Nat Genet,2019,51:202-206. 15 Yang XY,Ozawa S,Kato Y,et al.C-X-C motif chemokine ligand 14 is a unique multifunctional regulator of tumor progression.Int J Mol Sci,2019,20. 16 den Boon JA,Pyeon D,Wang SS,et al.Molecular transitions from papillomavirus infection to cervical precancer and cancer:Role of stromal estrogen receptor signaling.Proc Natl Acad Sci U S A,2015,112:E3255-3264. 17 Penk A,Baumann L,Huster D,et al.NMR and molecular modeling reveal specificity of the interactions between CXCL14 and glycosaminoglycans.Glycobiology,2019,29:715-725. 18 Fazi B,Proserpio C,Galardi S,et al.The Expression of the Chemokine CXCL14 correlates with several aggressive aspects of glioblastoma and promotes key properties of glioblastoma cells.Int J Mol Sci,2019,20.
